As cisplatin can also signal through p53 to modulate cancer cell apoptosis [28], it is uncertain whether either platinum compound would confer a functional advantage in NSCLC treatment by acting through TRAIL receptor signaling. Here, TP53 is linked to non-small cell lung carcinoma.